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Nonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma 
(HCC), especially in non-cirrhotic individuals. The rs641738 C > T MBOAT7/TMC4 variant predisposes to 
progressive NAFLD, but the impact on hepatic carcinogenesis is unknown. In Italian NAFLD patients, 
the rs641738 T allele was associated with NAFLD-HCC (OR 1.65, 1.08–2.55; n = 765), particularly in 
those without advanced fibrosis (p < 0.001). The risk T allele was linked to 3’-UTR variation in MBOAT7 
and to reduced MBOAT7 expression in patients without severe fibrosis. The number of PNPLA3, 
TM6SF2, and MBOAT7 risk variants was associated with NAFLD-HCC independently of clinical factors 
(p < 0.001), but did not significantly improve their predictive accuracy. When combining data from 
an independent UK NAFLD cohort, in the overall cohort of non-cirrhotic patients (n = 913, 41 with 
HCC) the T allele remained associated with HCC (OR 2.10, 1.33–3.31). Finally, in a combined cohort 
of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121), the T allele was 
independently associated with HCC risk (OR 1.93, 1.07–3.58). In conclusion, the MBOAT7 rs641738 T 
allele is associated with reduced MBOAT7 expression and may predispose to HCC in patients without 
cirrhosis, suggesting it should be evaluated in future prospective studies aimed at stratifying NAFLD-
HCC risk.
Following the epidemics of obesity and insulin resistance and the recent improvements in the prevention and 
treatment of viral hepatitis, nonalcoholic fatty liver disease (NAFLD) is becoming a major cause of hepatocel-
lular carcinoma (HCC) in Western countries1–4. NAFLD affects 16–38% of the general population worldwide5 
and is leading cause of cirrhosis, the main risk factor for HCC. However, HCC frequently develops in NAFLD 
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patients even in the absence of severe liver fibrosis6. The high prevalence of NAFLD and development of HCC in 
non-cirrhotic patients unaware of being at risk renders therefore classic HCC screening strategies aimed at early 
diagnosis and curative treatment7 unfeasible. Thus, there is an urgent need of non-invasive biomarkers able to 
stratify NAFLD-HCC risk, especially in patients without severe fibrosis8, 9.
Inherited factors contribute to HCC susceptibility, and strong familial aggregation is observed10. NAFLD too 
has a strong heritable component11, and the PNPLA3 I148M variant is the main common genetic determinant 
of hepatic fat content and of progressive NAFLD12–15. The mechanism is related to accumulation of the mutated 
protein16, which interferes with lipid droplets remodeling in hepatocytes15, 17, 18, and with retinol release by hepatic 
stellate cells19, 20. The PNPLA3 variant predicts HCC development in European patients with NAFLD21, suggest-
ing that genetic risk factors may prove helpful to select high-risk individuals for screening21–23, but has a low 
specificity to be used as single prognostic biomarker24. Furthermore, the PNPLA3 variant also predisposes to 
HCC in other liver diseases associated with steatosis, namely alcoholic liver disease (ALD) and chronic hepatitis 
C (CHC)23. The TM6SF2 E167K variant also predisposes to progressive NAFLD by altering the secretion of very 
low-density lipoproteins25–27, but its direct role in HCC predisposition is disputed26, 28.
The MBOAT7/TMC4 locus rs641738 C > T sequence variant predisposes to liver fibrosis development in indi-
viduals with excessive alcohol intake29 and chronic hepatitis C30, and to the development and the progression of 
NAFLD in individuals of European descent31, 32. However, whether the rs641738 variant is also associated with 
HCC risk is still unknown. Aim of this study was therefore to evaluate whether the rs641738 variant predisposes 
to HCC in NAFLD patients stratified by the presence of severe fibrosis, and in other liver diseases characterized 
by hepatic steatosis.
Results
The Italian NAFLD cohort. The clinical features of Italian NAFLD patients stratified by HCC diagnosis 
are presented in Table 1. Patients who developed HCC were older (p < 0.001), had higher prevalence of type 2 
diabetes (T2DM; p < 0.001), and of severe fibrosis (stage F3-F4) than those who did not (Table 1), whereas sex 
distribution and prevalence of obesity were not different (p = NS). Concerning genetic risk factors, at univariate 
analysis HCC development was associated with PNPLA3 and MBOAT7 variants (p < 0.001 and p = 0.003, respec-
tively; Table 1).
The clinical features of Italian NAFLD-HCC patients according to presence of severe fibrosis are reported in 
Table S1. Patients who developed HCC in the absence of severe fibrosis (n = 21, 17%) were more frequently males 
(p = 0.040), and carriers of the MBOAT7 rs641738 risk T allele (p = 0.006).
MBOAT7 variation is associated with NAFLD-HCC in Italian patients. The frequency distribution 
of the MBOAT7 rs641738 C > T polymorphism in Italian NAFLD patients stratified by the presence of HCC 
is shown in Fig. 1A. There was a significant over-representation of the rs641738 T allele in HCC vs. non-HCC 
NAFLD patients (p = 0.003, Fig. 1a and Table 1). In the NAFLD population, which was selected due to refer-
ral for suspected steatohepatitis/HCC, there was a borderline deviation from Hardy-Weinberg equilibrium for 
the frequency distribution of the rs641738 MBOAT7 variant (p = 0.03 in both groups). However, the frequency 
Hepatocellular carcinoma
pYes (n = 132) No (n = 633)
Age, years 67.0 ± 8.8 47.5 ± 12.3 <0.001
Sex, Female 25 (19) 163 (26) 0.25
Obesity, yes 39 (32) 202 (32) 0.99
T2DM, yes 84 (64) 124 (20) <0.001
Severe fibrosis, F3-4 111 (84) 99 (16) <0.001
PNPLA3, I148M <0.001
    I/I 31 (23) 231 (36)
    I/M 55 (42) 283 (45)
    M/M 46 (35) 120 (19)
TM6SF2, E167K 0.30
    E/E 109 (83) 538 (85)
    E/K 19 (14) 88 (14)
    K/K 4 (3) 7 (1)
MBOAT7, rs641738 
C > T 0.003
    C/C 26 (20) 213 (34)
    C/T 69 (52) 285 (45)
    T/T 37 (28) 135 (21)
Table 1. Clinical features of 765 Italian NAFLD patients stratified by HCC diagnosis. (): % values; T2DM: type 
2 diabetes mellitus. Comparisons were performed by logistic regression setting HCC as dependent variable, and 
the association of genetic variants was analyzed assuming additive models.
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distribution of the rs641738 variant did not violate Hardy-Weinberg equilibrium in 243 unselected healthy con-
trol subjects (p = NS; Table S3).
The clinical features of Italian NAFLD patients stratified by the rs641738 genotype are shown in Table S2. 
The rs641738 T allele was borderline associated with T2DM (p = 0.05) in the overall cohort, but this was not 
confirmed in patients stratified by HCC diagnosis, and was possibly explained by the confounding effect of the 
association between both rs641738 T allele and T2DM with HCC. In HCC patients, the T allele was associated 
with obesity (p = 0.035), and lack of severe fibrosis F3-F4 (p = 0.006).
As expected, the rs641738 T allele was nearly associated with severe fibrosis (stage F3-F4; OR 1.24, 95% c.i. 
1.00–1.54; p = 0.052). The frequency distribution of PNPLA3, TM6SF2, and MBOAT7 variants according to hepa-
tocellular carcinoma (HCC) diagnosis in Italian NAFLD patients stratified by the severity of fibrosis (stage F0-F2 
vs. F3-F4) is presented in Table 2. While the PNPLA3 variant was associated with HCC development in patients 
with (p = 0.011), but not in those without severe fibrosis (p = NS), the MBOAT7 T allele was associated with HCC 
in patients without (p < 0.001; Fig. 1b and Table 2), but not in those with (p = 0.55; Fig. 1c and Table 2) severe 
fibrosis.
Independent predictors of NAFLD-HCC. The independent predictors of NAFLD-HCC are presented in 
Table 3. At univariate analysis (left panel), development of HCC was associated with older age, T2DM, and severe 
fibrosis (p < 0.001 for all), whereas among the genetic factors with PNPLA3 I148M (p < 0.001) and MBOAT7 T 
rs641738 T alleles (OR 2.18, 95% c.i. 1.30–3.63; p = 0.003).
At multivariate logistic regression analysis including as independent variables noninvasive predictors of HCC 
(Model 1, middle panel), which can be applied even in NAFLD patients without histological evaluation of liver 
damage, HCC development was associated with older age (p < 0.001), male sex (p = 0.045), T2DM (p < 0.001), 
PNPLA3 I148M alleles (p = 0.010), TM6SF2 E167K alleles (p = 0.027), and remained strongly associated with 
MBOAT7 rs641738 alleles (OR 1.81, 95% c.i. 1.24–2.69; p = 0.002).
After further adjustment for the presence of severe fibrosis stage F3-F4 (Model 2), the TM6SF2 E167K 
(p = 0.008) and MBOAT7 rs641738 T (OR per allele 1.65, 95% c.i. 1.08–2.55; p = 0.021; OR for T/T vs. C/C 2.73, 
95% c.i. 1.17–6.51, p = 0.008) alleles remained significantly associated with HCC risk, whereas the effect of the 
PNPLA3 I148M variant was lost.
In Model 1, the effect of MBOAT7 variant was larger in patients without severe fibrosis (OR per allele 2.78, 
95% c.i. 1.04–8.71; p = 0.050), whereas it was not significant considering only patients with severe fibrosis (OR 
per allele 1.19, 95% c.i. 0.78–2.03; p = 0.3).
Combined effect of genetic risk factors for NAFLD-HCC. The relationship between the total number 
of risk alleles including PNPLA3 I148M, TM6SF2 E167K, and MBOAT7 rs641738 T and HCC risk is presented in 
Fig. 2. There was a significant association between the number of risk alleles and HCC (OR per allele 1.56, 95% c.i. 
Figure 1. Frequency distribution of the MBOAT7 locus rs641738 T allele in 765 Italian NAFLD patients 
stratified by the presence of hepatocellular carcinoma (HCC). (a) Overall cohort; (b) patients with stage F0-F2 
fibrosis; (c) patients with stage F3-F4 fibrosis. Comparisons were performed by logistic regression setting HCC 
as dependent variable, and the association with the MBOAT7 variant was analyzed assuming an additive model.
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1.31–1.86; OR 9.25, 95% c.i. 3.83–22.8 between the extremes of the distribution, i.e. 5 vs. 0 risk alleles; p < 0.001 
for both). HCC risk was 9% in the 36% of the population with 0–1 risk alleles, 19% in the 55% of the population 
with 2–3 risk alleles, and 31% in the 9% of the population with 4–5 risk alleles. The association held constant after 
correction for other risk factors as in Model 2 (OR per allele 1.68, 95% c.i. 1.30–2.20; OR 13.4, 95% c.i. 3.71–51.5 
between the extremes of the distribution; p < 0.001 for both).
A combined risk score considering acquired and genetic risk factors was developed to predict HCC: 1/
(1 + e− ((−12.588 + (0.162 * age) + (0.404 * Sex: 1 if male, −1 if female) + (0.259 * Obesity: 1 present, −1 
absent) + (0.587 * T2DM: 1 present, −1 absent) + (1.299 * Severe Fibrosis: 1 yes, −1 no) + (0.442 * number of 
risk alleles))). The model had a 0.96 ± 0.4 area under the receiving operating characteristic curve (AUROC) for 
detecting HCC cases. The optimal cutoff (identifying the best combination of sensitivity and specificity) had 96% 
sensitivity and 89% specificity for HCC (Fig. S1). The corresponding AUROC of a model taking into consider-
ation only clinical factors was slightly lower (0.93 ± 0.5). In the subgroup of patients without severe fibrosis, the 
AUROC for clinical factors alone was 0.91 ± 0.5, whereas the full model incorporating genetic risk factors main-
tained an AUROC of 0.96 ± 0.4 (p = NS vs. clinical factors alone).
Relationship between MBOAT7 locus variants and gene expression. To investigate the biological 
basis for the stronger association of MBOAT7 locus variation with HCC in patients without severe fibrosis, we 
next examined the association of the rs641738 variant with possibly variants that may influence MBOAT7 mRNA 
stability, and with hepatic MBOAT7 mRNA expression levels in patients stratified by the severity of liver fibrosis.
In 98 severely obese patients, the rs641738 variant was in high linkage with the MBOAT7 3′-UTR variant 
rs8736 C > T polymorphism (R2 = 0.98; only 1/98 discordant case). Despite this, the rs8736 polymorphism 
was non-significantly more closely associated with NAFLD (p = 0.048 vs. p = 0.057) and MBOAT7 expression 
Fibrosis stage
HCC
F0-F2
p
F3-F4
p
Yes No Yes No
Yes 
(n = 21) No (n = 534)
Yes 
(n = 111)
No 
(n = 99)
PNPLA3, I148M 0.92 0.011
    I/I 10 (48) 200 (37) 21 (19) 31 (31)
    I/M 6 (28) 236 (44) 49 (44) 47 (48)
    M/M 5 (24) 98 (19) 41 (37) 22 (22)
TM6SF2, E167K 0.11 0.50
    E/E 16 (76) 458 (86) 93 (84) 80 (80)
    E/K 4 (19) 70 (13) 15 (13) 18 (19)
    K/K 1 (5) 6 (1) 3 (3) 1 (1)
MBOAT7, rs641738 <0.001 0.55
    C/C 1 (4) 183 (35) 25 (22) 30 (30)
    C/T 10 (48) 243 (45) 59 (53) 42 (43)
    T/T 10 (48) 108 (20) 27 (25) 27 (27)
Table 2. Frequency distribution of PNPLA3, TM6SF2, and MBOAT7 variants according to hepatocellular 
carcinoma (HCC) in 765 Italian NAFLD patients stratified by the severity of fibrosis (stage F0-F2 vs. F3-F4). (): 
% values. HCC. Hepatocellular carcinoma. Comparisons were performed by logistic regression setting HCC as 
dependent variable, and the association of genetic variants was analyzed assuming additive models.
Unadjusted Model 1 Model 2
OR 95% c.i. p OR 95% c.i. p OR 95% c.i. p
Age, years 1.20 1.16–1.24 <0.001 1.19 1.15–1.23 <0.001 1.16 1.11–1.21 <0.001
Sex, Female 0.57 0.41–1.06 0.09 0.52 0.27–0.99 0.045 0.45 0.21–0.91 0.026
Obesity, yes 1.11 0.75–1.69 0.61 1.69 1.05–2.56 0.069 2.50 1.32–4.76 0.008
T2DM, yes 7.18 4.81–10.84 <0.001 4.73 2.75–8.30 <0.001 3.33 1.75–6.44 <0.001
Severe fibrosis, F3-F4 28.9 17.6–49.5 <0.001 NA NA NA 12.5 6.36–6.1 <0.001
PNPLA3, n I148M alleles 1.70 1.32–2.21 <0.001 1.61 1.12–2.32 0.010 1.31 0.86–2.03 0.24
TM6SF2, n E167K alleles 1.27 0.82–1.92 0.27 1.99 1.08–3.65 0.027 2.80 1.33–6.10 0.008
MBOAT7, n T alleles 2.18 1.30–3.63 0.003 1.81 1.24–2.69 0.002 1.65 1.08–2.55 0.021
Table 3. Independent predictors of HCC in 765 Italian patients with NAFLD. OR: odds ratio of HCC, 95% 
c.i.: 95% confidence interval; T2DM: type 2 diabetes mellitus; n: number of at risk alleles. Comparisons were 
performed by logistic regression setting HCC as dependent variable, and the association of genetic variants 
was analyzed assuming additive models. Model 1: adjusted for age, sex, obesity, and T2DM; Model 2: further 
adjusted for presence of advanced fibrosis; NA: not addressed.
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(p = 0.042 vs. p = 0.046) than rs641738. These data are in line with the hypothesis that rs641738 is not the causal 
variant, but may be in linkage with variants influencing MBOAT7 expression.
Gene expression of MBOAT7 in 47 patients from the Hepatology service characterized by more severe liver 
damage (Table S4) is shown in Fig. 3. The rs641738 T allele was associated with reduced hepatic MBOAT7 expres-
sion in patients absent or mild fibrosis (stage F0-F1; p = 0.02), but not in those with moderate-severe fibrosis 
(stage F2-F4; p = 0.1).
MBOAT7 variation and NAFLD-HCC risk in UK non-cirrhotic NAFLD patients. To increase the 
study power, we next evaluated the association of the rs641738 T allele with HCC risk in non-cirrhotic NAFLD 
patients from UK, whose clinical features are presented in Table S5. The frequency distribution of the rs641738 
C > T genotype in patients stratified by HCC diagnosis is shown in Table 4. Although in the UK non-cirrhotic 
NAFLD cohort (N = 358, of whom 20 with HCC) MBOAT7 variation was not significantly associated with HCC 
(p = 0.32), in the overall combined UK/Italian cohort of NAFLD patients without advanced fibrosis/cirrhosis the 
T allele remained associated with an increased risk of HCC (allelic OR 2.10, 95% c.i. 1.33–3.31).
Impact of MBOAT7 variation on HCC risk in non-cirrhotic patients with other liver diseases. We 
finally evaluated the impact of the rs641738 T allele on HCC risk in 1121 non-cirrhotic patients with CHC and 
ALD (25, 2% with HCC, Table S6). Results are presented in Table 5. The rs641738 T allele was associated with 
increased risk of HCC, independently of age, sex, and the etiology of liver disease (OR 1.93 for each T allele, 
95% c.i. 1.07–3.58; p = 0.035), with an effect size comparable to that observed in NAFLD. We observed a similar 
Figure 2. Risk of hepatocellular carcinoma according to the number of PNPLA3 I148M, TM6SF2 E167K, and 
MBOAT7 rs641738 C > T risk variants in 765 Italian patients with NAFLD. HCC: hepatocellular carcinoma; SE: 
standard error. Comparisons were performed by a multivariate logistic regression setting HCC as dependent 
variable, and the association with genetic risk factors (numbers of at risk alleles carried) was analyzed assuming 
an additive model. p < 0.001 for the association of the number of risk alleles with HCC, both at unadjusted 
analysis and after adjustment for age, sex, obesity, T2DM, and presence of advanced fibrosis stage F2-F4.
Figure 3. Impact of the presence of rs643718 risk T allele on MBOAT7 expression (log mRNA levels) in 47 
patients with NAFLD from the Milan Hepatology service stratified by the presence of clinically significant 
hepatic fibrosis (stage F2-F4). Data were compared by Student’s t-test.
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trend for association of the T allele with non-cirrhotic HCC in patients with CHC and ALD analyzed separately 
(Table S7). The PNPLA3 I148M variant was also associated with HCC development outside cirrhosis, with a sim-
ilar effect size of that of MBOAT7 variation (Table 5; p = 0.021).
Discussion
In this study, we evaluated whether the rs641738 C > T MBOAT7 locus sequence variant, associated with the 
development and progression of NAFLD31, 32, influences susceptibility to NAFLD-HCC. The main result is that 
in the Italian NAFLD cohort each MBOAT7 rs641738 T allele conferred an approximately 80% increased risk of 
HCC. The association was mostly driven by a strong enrichment in the risk T allele in patients without advanced 
liver fibrosis, suggesting that MBOAT7 variation predisposes to HCC development particularly in non-cirrhotic 
patients. To confirm this hypothesis, we also examined the frequency of the MBOAT7 T allele in an independ-
ent UK cohort of non-cirrhotic NAFLD patients. Although the T allele was not significantly associated with 
NAFLD-HCC in this replication cohort, it remained significant in the combined cohort of 913 non-cirrhotic 
European NAFLD patients (41 with HCC) where it was associated with a greater than 2-fold increased risk of 
NAFLD-HCC; a relatively large effect size for a common genetic variant. This genetic polymorphism might thus 
represent a first useful biomarker to stratify HCC risk among individuals affected by NAFLD without advanced 
liver fibrosis.
The MBOAT7 protein catalyzes the transfer of polyunsaturated fatty acids such as arachidonoyl-CoA to 
lyso-phosphatidylinositol, thereby allowing to achieve an adequate level of desaturation in cell membranes31. The 
rs641738 T allele is associated with reduced MBOAT7 expression and altered phosphatidyl-inositol plasma and 
hepatic composition31, 32, favoring hepatocellular fat accumulation and the production of inflammatory medi-
ators31. However, rs641738 is not likely the causal variant underpinning susceptibility to NAFLD and HCC, as 
we observed that it is in strong linkage with other polymorphisms in 3′-UTR of MBOAT7, which may be more 
closely related to the phenotype and are potentially involved in the regulation of MBOAT7 mRNA stability.
Hepatocellular carcinoma
YES NO p* OR (95% c.i.)
Italy, n= 21 534
MBOAT7, rs641738 C > T <0.001 3.09 (1.58–6.02)
C/C 1 (4) 183 (35)
C/T 10 (48) 243 (45)
T/T 10 (48) 108 (20)
UK, n= 20 338
MBOAT7, rs641738 C > T 0.32 1.39 (0.71–2.71)
C/C 4 (20) 97 (29)
C/T 11 (55) 179 (53)
T/T 5 (25) 62 (18)
OVERALL, n= 41 872
MBOAT7, rs641738 C > T 0.001 2.10 (1.33–3.31)
C/C 5 (12) 280 (32)
C/T 21 (51) 422 (49)
T/T 15 (37) 170 (19)
Table 4. Frequency distribution of the rs641738 C > T genotype in 913 patients without advanced liver fibrosis/
cirrhosis from the Italian and UK cohorts stratified by HCC diagnosis. *Comparisons were performed by 
logistic regression setting HCC as dependent variable, and the association of genetic variants was analyzed 
assuming additive models. (): % values; OR, 95% c.i.: allelic odds ratio and 95% confidence intervals.
HCC
No (n = 1096) Yes (n = 25) p value Allelic OR, 95% c.i.* p value*
PNPLA3 I148M 558/437/101 (51/40/9) 8/10/7 (32/40/28) 0.016 1.92, 1.07–3.45 0.021
TM6SF2 E167K 973/122/1 (89/11/0) 20/5 (80/20) 0.16 1.96, 0.61–5.27 0.16
MBOAT7/TMC4 
rs641738 C > T 327/510/259 (30/46/24) 2/15/8 (8/60/32) 0.028 1.93, 1.07–3.58 0.035
Table 5. Independent predictors of hepatocellular carcinoma (HCC) in 1121 non-cirrhotic patients with 
chronic liver diseases associated with hepatic fat accumulation (597 with chronic hepatitis C and 524 with 
alcoholic liver disease). (): % values; OR: odds ratio; c.i.: confidence interval. Comparisons were performed 
by logistic regression setting HCC as dependent variable, and the association of genetic variants was analyzed 
assuming additive models. * Adjusted for age, sex, liver disease etiology, and PNPLA3, TM6SF2 and MBOAT7/
TMC4 genetic variants.
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It could be speculated that the effect size of rs641738 on HCC risk was larger in patients without severe fibrosis 
because the presence of the risk variant may somewhat compensate for the lack of the cirrhotic pro-carcinogenic 
environment. However, we observed that the rs641738 T allele is associated with reduced hepatic expression of 
MBOAT731 only in NAFLD patients without severe fibrosis. Therefore, the MBOAT7 variant may exert its dele-
terious effect specifically at early stages of liver disease. Alteration of hepatic parenchymal structure and relative 
cell-types representation may then hamper the impact of the MBOAT7 variant during severe fibrosis, because 
MBOAT7 is highly expressed in hepatic stellate cells and inflammatory cells31, 33. In keeping with this interpreta-
tion, the rs641738 T allele was also associated with development of early stages, but not severe fibrosis in patients 
at risk of NASH31, and in a large cohort of CHC patients30. Therefore, the MBOAT7 variation might have a dual 
impact on liver disease during initial stages: either predisposes to HCC development before severe fibrosis ensues, 
or it facilitates the evolution to early-intermediate fibrosis. In line with this hypothesis, we also showed that the 
rs641738 T allele was associated with HCC development in non-cirrhotic patients with ALD or CHC.
In the Italian NAFLD cohort, the overall impact of the MBOAT7 rs641738 on HCC risk was similar to that of 
the I148M PNPLA3 variant. However, the effect of the I148M variant on HCC risk was not independent of severe 
fibrosis, suggesting that the mechanism is partly mediated by promotion of hepatic fibrogenesis and alteration 
of hepatic stellate cells biology15, 19, 34. Notably, the size effect of the PNPLA3 I148M variant was larger and only 
partially attenuated by the impact on liver fibrosis in a previous study conducted in a UK cohort21. This differ-
ence may be due to lifestyle factors, and to the higher prevalence of clinical cofactors, as opposed to genetic risk 
variants (lower frequency of the I148M variant) in the UK cohort. In addition, we also report for the first time an 
association between the TM6SF2 E167K variant and NAFLD-HCC. However, this association was not detected 
by univariate analysis due to an interaction of the TM6SF2 variant with clinical factors, and it has previously been 
absent when sought in the UK NAFLD cohort26, whereas a predisposing effect on HCC was reported in a Italian 
cohort of patients with alcoholic cirrhosis28. Further studies are therefore required to confirm whether the E167K 
variant is an independent risk factor for HCC.
All in all, data suggest that genetic variants predisposing to hepatic fat accumulation promote hepatic carcino-
genesis. Indeed, hepatocellular fat accumulation represents a key feature of hepatic carcinogenesis35, 36. Therefore, 
they might represent useful biomarkers for risk stratification. In fact, in the Italian NAFLD cohort the number of 
genetic risk variants carried was strongly associated with HCC, with 13.4-fold higher risk in those carrying five 
risk variants as compared to none. Remarkably, the number of genetic risk variants was able to classify NAFLD 
patients in three groups with different HCC risk: 9% in the 36% of patients with 0–1 risk alleles, l9% in the 55% 
with 2–3 risk alleles, and 31% in those carrying more than 3 risk alleles. This could in principle allow a better 
stratification of HCC risk than those allowed by the PNPLA3 I148M variant alone, which was proposed by the 
EASL-EASD-EASO NAFLD guidelines21, 37. However, in the present cross-sectional Italian cohort genetic risk 
variants did not significantly improve the predictive accuracy of clinical factors.
Limitations of the study include its cross-sectional retrospective nature, resulting similarly to previous 
reports21 in an uneven representation of clinical risk factors (age, sex, T2DM, severe fibrosis) between HCC 
cases and controls. However, the majority of NAFLD-HCC patients are still diagnosed incidentally outside reg-
ular follow-up38, so that prospective studies in patients with advanced disease would not be more informative, 
especially for the risk of non-cirrhotic NAFLD-HCC. This could have led to an underestimation of the impact of 
inherited genetic risk variants on NAFLD-HCC, whereas the impact of clinical risk factors may have been overes-
timated. Therefore, the weight of specific factors in determining the HCC risk score should be reassessed in larger 
prospective cohorts with long follow-up and availability of the genetic risk profile before evaluation of genetic risk 
variants can be considered for implementation in clinical practice. Due to the relatively low number of patients 
included, these limitations are particularly relevant for the association of MBOAT7 variation with HCC develop-
ment in patients without severe liver fibrosis. Finally, these results may not be applicable to other ethnic groups.
In conclusion, the MBOAT7 rs641738 T allele is associated with reduced MBOAT7 expression and may pre-
dispose to HCC in European individuals without cirrhosis, suggesting it should be evaluated in future prospective 
studies aimed at stratifying NAFLD-HCC risk.
Methods
Patients. We enrolled 132 consecutive unrelated patients with NAFLD-HCC of Italian descent, referred 
between January 2008 and January 2015 to the Milan, Udine, Turin, Rome, and Palermo hospitals, for whom 
DNA samples were available. Diagnosis of HCC was based on the EASL–EORTC Clinical Practice Guidelines7. 
In the absence of liver biopsy, diagnosis of NAFLD required detection of ultrasonographic steatosis plus at least 
one criterion of the metabolic syndrome.
As controls, we selected Italian-ancestry patients with histologically confirmed NAFLD followed at the same 
referral outpatient Hepatology services during the same study period27, 39, from a recently published database31, 
who did not develop HCC during follow-up. We did not consider for this study bariatric patients from Milan 
because of the different recruitment criteria (indication to metabolic surgery), leading to different demographic 
and clinical features27, 39, and the lack of incident HCC cases in the cohort.
All patients were tested for secondary causes of steatosis including alcohol abuse (≥30/20 g/day in M/F) and 
the use of drugs known to precipitate steatosis. Viral and autoimmune hepatitis, hereditary hemochromatosis, 
Wilson’s disease, alpha-1-antitrypsin deficiency and present or previous active infection with HBV and HCV were 
ruled out using standard clinical and laboratory evaluation, as well as liver biopsy features.
Advanced fibrosis was defined in the presence of fibrosis stage F3-F440, when liver biopsy was available. In 
HCC patients with radiological diagnosis, advanced fibrosis was defined in the presence of clinical, endoscopic or 
ultrasonographic signs of portal hypertension or cirrhosis (n = 46), or of liver stiffness ≥8.4 kPa evaluated by elas-
tometry (n = 3), or by a positive NAFLD fibrosis score (n = 5)41. Obesity was defined when BMI > 30 Kg/m2. All 
NAFLD patients without HCC included in the study underwent liver biopsy, while among those who developed 
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HCC, fibrosis staging was histologically performed in 78 (59%) of the cases. Clinical features of subjects included 
according to the presence of HCC are shown in Table 1.
The UK NAFLD cohort comprising HCC cases and controls recruited at a single tertiary centre (the Newcastle 
upon Tyne Hospitals NHS Foundation Trust, UK) has previously been described21. The study had all the nec-
essary ethical approvals and all participants gave informed consent. For this study, we considered patients for 
whom liver disease staging scored according to the NASH CRN histopathological system and DNA samples for 
MBOAT7 genotyping were available. Clinical features of the 358 individuals analyzed in this study are presented 
in Table S5.
We next evaluated the impact of the rs641738 variant on HCC risk in an Italian multicenter cohort of 
non-cirrhotic patients with chronic hepatitis C (CHC; n = 597) and alcoholic liver disease (ALD; n = 524). CHC 
patients were from the well-described histological Milan CHC cohort42, 43, whereas HCC cases were previously 
described by our group (Milan HCC cohort, where presence of cirrhosis was carefully assessed)44.
ALD patients with and without HCC included patients from the Milan center, which were partly described 
previously (again the Milan HCC cohort), and for whom liver disease was evaluated by histology or as described 
above for NAFLD44. We also considered consecutive individuals, who were admitted to the Outpatient Clinic at 
the Department of Clinical Medicine, Policlinico Umberto I, Rome for alcohol abuse or dependence between 
2005 and 2014, for whom DNA samples were still available and genotyping was successful45. At-risk alcohol con-
sumption was defined as ≥3/2 alcohol units per day for M/F, respectively. Cirrhosis was ruled out based on the 
presence of at least one of the following features: (i) current or past cirrhosis complications; (ii) the presence of at 
least two parameters among hyperbilirubinaemia, hypoalbuminaemia, prolonged prothrombin time, low platelet 
count, irregular liver surface at ultrasound/CT, reduced portal vein flow at ultrasound, gastroesophageal varices 
at endoscopy, or by histological analysis. Individuals with other coexistent liver diseases were excluded. Clinical 
features of this cohort are presented in Table S6.
The study protocol was conformed to the ethical guidelines of the 1975 Declaration of Helsinki, was approved 
by the Ethical Committee of the Fondazione IRCCS Ca’ Granda of Milan, as well as by the other involved 
Institutions, and was performed according to the recommendations of the hospitals involved. Informed consent 
was obtained from each patient.
Genotyping. Patients were genotyped for rs738409 (PNPLA3 I148M) rs58542926 (TM6SF2 E167K), as previ-
ously described27. The rs641738 (located within TMC4 coding sequence, chr19:54676763 positive strand, p.G17E 
protein variant) and rs8736 (located within the 3′-untranslated region – UTR – of MBOAT7) MBOAT7/TMC4 
locus genotyping has been performed in duplicate by TaqMan 5′-nuclease assays at the Metabolic Liver Disease 
lab, at the University of Milan (Life Technologies, Carlsbad, CA). Genotyping success rate was >98%. The dupli-
cate genotype concordance rate was 100%. Genotyping was confirmed by direct sequencing of random samples, 
and concordance rate was 100% (primers are available upon demand).
Gene expression analysis. Expression of MBOAT7 and TMC4 was determined in two different subsets of 
patients. The first one was made of 98 severely obese patients, with a very low prevalence of advanced liver fibro-
sis, and has previously been described in details31. This was used to analyze the association of a 3′-untranslated 
region MBOAT7 locus variant, rs8736 possibly influencing MBOAT7 mRNA stability, with MBOAT7 expression. 
The second one was made up of 47 patients from the Hepatology service, and was characterized by a higher prev-
alence of liver fibrosis. Clinical features of these patients are presented in Table S4. This was used to evaluate the 
impact of liver fibrosis on the association between the rs641738 variant and MBOAT7 expression.
MBOAT7 expression was quantified as previously described31. Association analysis between rs641738 vari-
ant (additive model) and gene expression, and linkage with rs8736 were conducted by the PLINK v1.07 genetic 
analysis software.
Statistical analysis. For descriptive statistics, continuous variables are shown as mean and standard devia-
tion or median. Categorical variables are presented as number and proportion. The OR of HCC or severe fibrosis 
per MBOAT7 rs641738 T alleles and other risk factors were estimated by logistic regression models, assuming 
an additive effect of genetic variants, and adjusted for clinical risk factors (the major known clinical risk factors 
for NAFLD-HCC in previous studies) as specified, PNPLA3 I148M and TM6SF2 E167K genotypes (clinical and 
genetic factors previously associated with or candidate for liver disease evolution to HCC)21, 26. A NAFLD-HCC 
risk score was developed according to a previously described procedure41.
Statistical analyses were carried out using the JMP 13.0 Statistical analysis software (SAS Institute, Cary, NC), 
R statistical analysis software version 3.3.2 (http://www.R-project.org/), and PLINK v1.0746. P-values < 0.05 were 
considered statistically significant. The study methods and results have been reported according to the STROBE/
STREGA guidelines for genetic association studies.
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